Myriad Genetics (NASDAQ: MYGN) announced on Thursday that its Chief Executive Officer, Mark Capone, was resigning. Capone served as CEO since 2015 and was with the company for 17 years. CFO Bryan Riggsbee was named interim CEO.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,